Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension
Purpose To compare the efficacy and safety of brimonidine 0.2% vs unoprostone 0.15%, both added to timolol maleate 0.5% each given twice daily. Methods In this prospective, multi-centred, double-masked, crossover comparison, patients were randomized to one treatment group for a 6-week treatment peri...
Gespeichert in:
| Veröffentlicht in: | Eye (London) 2005-01, Vol.19 (1), p.35-40 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 40 |
|---|---|
| container_issue | 1 |
| container_start_page | 35 |
| container_title | Eye (London) |
| container_volume | 19 |
| creator | Sharpe, E D Henry, C J Mundorf, T K Day, D G Stewart, J A Jenkins, J N Stewart, W C |
| description | Purpose
To compare the efficacy and safety of brimonidine 0.2%
vs
unoprostone 0.15%, both added to timolol maleate 0.5% each given twice daily.
Methods
In this prospective, multi-centred, double-masked, crossover comparison, patients were randomized to one treatment group for a 6-week treatment period, and then crossed over to the opposite treatment. Measurements were performed at 0800, 1000, 1600, 1800, and 2000 h at baseline and at the end of each treatment period.
Results
In all, 33 patients entered this trial and 29 completed. The baseline trough intraocular pressure (IOP) was 23.3±2.4 and the diurnal curve IOP was 22.0±1.3 mmHg. For the brimonidine and timolol maleate treatment group, the trough IOP was 21.6±3.3 and the diurnal curve IOP was 19.8±2.1 mmHg, while the timolol and unoprostone treatment showed a trough IOP of 20.9±3.8 and a diurnal curve IOP of 19.3±2.4 mmHg. There was no significant difference between treatment groups at any time point for the diurnal curve, or in the reduction from baseline (
P
>0.05). Both treatments failed to statistically reduce the IOP from baseline at 1800 h. There was no difference between treatment groups regarding ocular and systemic unsolicited adverse events, but patients admitted to more dryness (
P
=0.02) and burning upon instillation (
P |
| doi_str_mv | 10.1038/sj.eye.6701392 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_218342977</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>971591031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-9298620e9b102a0193b191ec386cd4f7cff7dd98c19bf9b7ea0c15abccacc2463</originalsourceid><addsrcrecordid>eNp1kU9v1DAQxS0EotvClSOykPaY1H-SOD5CBQWpEheQuEWOPdl65bWD7bTaL8NnxctG2hMnS57fvDczD6F3lNSU8P427Ws4Qt0JQrlkL9CGNqKr2qZtXqINkS2pGGO_rtB1SntCSlGQ1-iKtkQ2gvMN-vMp2kPw1lgPmNRsi58SXnyYY0g5_Puj7RaPIT9iZQwYnAPOpcUFhw_KgconpiA7-wQe52erARtl3fFEzipb8DnhZ1sE5uKl4hGHGXyl_M4B3jm16HBQOEQc9OJUxI_HGWIGn2zwb9CrSbkEb9f3Bv388vnH3dfq4fv9t7uPD5VuOMmVZLLvGAE5UsIUoZKPVFLQvO-0aSahp0kYI3tN5TjJUYAimrZq1FppzZqO36APZ92y9-8FUh72YYm-WA6M9rxhUogC1WdIl-OkCNOwLjRQMpzSGNJ-KGkMaxql4f2quowHMBd8PX8BtiugklZuisprmy5cV8JkzYm7PXOplPwO4mW8_1j_BYaDpME</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218342977</pqid></control><display><type>article</type><title>Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Sharpe, E D ; Henry, C J ; Mundorf, T K ; Day, D G ; Stewart, J A ; Jenkins, J N ; Stewart, W C</creator><creatorcontrib>Sharpe, E D ; Henry, C J ; Mundorf, T K ; Day, D G ; Stewart, J A ; Jenkins, J N ; Stewart, W C</creatorcontrib><description>Purpose
To compare the efficacy and safety of brimonidine 0.2%
vs
unoprostone 0.15%, both added to timolol maleate 0.5% each given twice daily.
Methods
In this prospective, multi-centred, double-masked, crossover comparison, patients were randomized to one treatment group for a 6-week treatment period, and then crossed over to the opposite treatment. Measurements were performed at 0800, 1000, 1600, 1800, and 2000 h at baseline and at the end of each treatment period.
Results
In all, 33 patients entered this trial and 29 completed. The baseline trough intraocular pressure (IOP) was 23.3±2.4 and the diurnal curve IOP was 22.0±1.3 mmHg. For the brimonidine and timolol maleate treatment group, the trough IOP was 21.6±3.3 and the diurnal curve IOP was 19.8±2.1 mmHg, while the timolol and unoprostone treatment showed a trough IOP of 20.9±3.8 and a diurnal curve IOP of 19.3±2.4 mmHg. There was no significant difference between treatment groups at any time point for the diurnal curve, or in the reduction from baseline (
P
>0.05). Both treatments failed to statistically reduce the IOP from baseline at 1800 h. There was no difference between treatment groups regarding ocular and systemic unsolicited adverse events, but patients admitted to more dryness (
P
=0.02) and burning upon instillation (
P
<0.0001) with unoprostone by survey.
Conclusion
Brimonidine 0.2% or unoprostone 0.15% added to timolol maleate 0.5% provide similar efficacy and safety throughout the daytime diurnal curve.</description><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/sj.eye.6701392</identifier><identifier>PMID: 15094733</identifier><identifier>CODEN: EYEEEC</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject><![CDATA[Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - adverse effects ; Biological and medical sciences ; Brimonidine Tartrate ; clinical-study ; Cross-Over Studies ; Dinoprost - administration & dosage ; Dinoprost - adverse effects ; Dinoprost - analogs & derivatives ; Double-Blind Method ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Glaucoma ; Glaucoma and intraocular pressure ; Glaucoma, Open-Angle - drug therapy ; Glaucoma, Open-Angle - physiopathology ; Humans ; Intraocular Pressure - drug effects ; Laboratory Medicine ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Ocular Hypertension - drug therapy ; Ophthalmology ; Pharmaceutical Sciences/Technology ; Prospective Studies ; Quinoxalines - administration & dosage ; Quinoxalines - adverse effects ; Surgery ; Surgical Oncology ; Timolol - administration & dosage ; Timolol - adverse effects ; Treatment Outcome]]></subject><ispartof>Eye (London), 2005-01, Vol.19 (1), p.35-40</ispartof><rights>Royal College of Ophthalmologists 2005</rights><rights>2005 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jan 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-9298620e9b102a0193b191ec386cd4f7cff7dd98c19bf9b7ea0c15abccacc2463</citedby><cites>FETCH-LOGICAL-c430t-9298620e9b102a0193b191ec386cd4f7cff7dd98c19bf9b7ea0c15abccacc2463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.eye.6701392$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.eye.6701392$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16476243$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15094733$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sharpe, E D</creatorcontrib><creatorcontrib>Henry, C J</creatorcontrib><creatorcontrib>Mundorf, T K</creatorcontrib><creatorcontrib>Day, D G</creatorcontrib><creatorcontrib>Stewart, J A</creatorcontrib><creatorcontrib>Jenkins, J N</creatorcontrib><creatorcontrib>Stewart, W C</creatorcontrib><title>Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><description>Purpose
To compare the efficacy and safety of brimonidine 0.2%
vs
unoprostone 0.15%, both added to timolol maleate 0.5% each given twice daily.
Methods
In this prospective, multi-centred, double-masked, crossover comparison, patients were randomized to one treatment group for a 6-week treatment period, and then crossed over to the opposite treatment. Measurements were performed at 0800, 1000, 1600, 1800, and 2000 h at baseline and at the end of each treatment period.
Results
In all, 33 patients entered this trial and 29 completed. The baseline trough intraocular pressure (IOP) was 23.3±2.4 and the diurnal curve IOP was 22.0±1.3 mmHg. For the brimonidine and timolol maleate treatment group, the trough IOP was 21.6±3.3 and the diurnal curve IOP was 19.8±2.1 mmHg, while the timolol and unoprostone treatment showed a trough IOP of 20.9±3.8 and a diurnal curve IOP of 19.3±2.4 mmHg. There was no significant difference between treatment groups at any time point for the diurnal curve, or in the reduction from baseline (
P
>0.05). Both treatments failed to statistically reduce the IOP from baseline at 1800 h. There was no difference between treatment groups regarding ocular and systemic unsolicited adverse events, but patients admitted to more dryness (
P
=0.02) and burning upon instillation (
P
<0.0001) with unoprostone by survey.
Conclusion
Brimonidine 0.2% or unoprostone 0.15% added to timolol maleate 0.5% provide similar efficacy and safety throughout the daytime diurnal curve.</description><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Brimonidine Tartrate</subject><subject>clinical-study</subject><subject>Cross-Over Studies</subject><subject>Dinoprost - administration & dosage</subject><subject>Dinoprost - adverse effects</subject><subject>Dinoprost - analogs & derivatives</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Glaucoma</subject><subject>Glaucoma and intraocular pressure</subject><subject>Glaucoma, Open-Angle - drug therapy</subject><subject>Glaucoma, Open-Angle - physiopathology</subject><subject>Humans</subject><subject>Intraocular Pressure - drug effects</subject><subject>Laboratory Medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Ocular Hypertension - drug therapy</subject><subject>Ophthalmology</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Prospective Studies</subject><subject>Quinoxalines - administration & dosage</subject><subject>Quinoxalines - adverse effects</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Timolol - administration & dosage</subject><subject>Timolol - adverse effects</subject><subject>Treatment Outcome</subject><issn>0950-222X</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU9v1DAQxS0EotvClSOykPaY1H-SOD5CBQWpEheQuEWOPdl65bWD7bTaL8NnxctG2hMnS57fvDczD6F3lNSU8P427Ws4Qt0JQrlkL9CGNqKr2qZtXqINkS2pGGO_rtB1SntCSlGQ1-iKtkQ2gvMN-vMp2kPw1lgPmNRsi58SXnyYY0g5_Puj7RaPIT9iZQwYnAPOpcUFhw_KgconpiA7-wQe52erARtl3fFEzipb8DnhZ1sE5uKl4hGHGXyl_M4B3jm16HBQOEQc9OJUxI_HGWIGn2zwb9CrSbkEb9f3Bv388vnH3dfq4fv9t7uPD5VuOMmVZLLvGAE5UsIUoZKPVFLQvO-0aSahp0kYI3tN5TjJUYAimrZq1FppzZqO36APZ92y9-8FUh72YYm-WA6M9rxhUogC1WdIl-OkCNOwLjRQMpzSGNJ-KGkMaxql4f2quowHMBd8PX8BtiugklZuisprmy5cV8JkzYm7PXOplPwO4mW8_1j_BYaDpME</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>Sharpe, E D</creator><creator>Henry, C J</creator><creator>Mundorf, T K</creator><creator>Day, D G</creator><creator>Stewart, J A</creator><creator>Jenkins, J N</creator><creator>Stewart, W C</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20050101</creationdate><title>Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension</title><author>Sharpe, E D ; Henry, C J ; Mundorf, T K ; Day, D G ; Stewart, J A ; Jenkins, J N ; Stewart, W C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-9298620e9b102a0193b191ec386cd4f7cff7dd98c19bf9b7ea0c15abccacc2463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Brimonidine Tartrate</topic><topic>clinical-study</topic><topic>Cross-Over Studies</topic><topic>Dinoprost - administration & dosage</topic><topic>Dinoprost - adverse effects</topic><topic>Dinoprost - analogs & derivatives</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Glaucoma</topic><topic>Glaucoma and intraocular pressure</topic><topic>Glaucoma, Open-Angle - drug therapy</topic><topic>Glaucoma, Open-Angle - physiopathology</topic><topic>Humans</topic><topic>Intraocular Pressure - drug effects</topic><topic>Laboratory Medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Ocular Hypertension - drug therapy</topic><topic>Ophthalmology</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Prospective Studies</topic><topic>Quinoxalines - administration & dosage</topic><topic>Quinoxalines - adverse effects</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Timolol - administration & dosage</topic><topic>Timolol - adverse effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sharpe, E D</creatorcontrib><creatorcontrib>Henry, C J</creatorcontrib><creatorcontrib>Mundorf, T K</creatorcontrib><creatorcontrib>Day, D G</creatorcontrib><creatorcontrib>Stewart, J A</creatorcontrib><creatorcontrib>Jenkins, J N</creatorcontrib><creatorcontrib>Stewart, W C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sharpe, E D</au><au>Henry, C J</au><au>Mundorf, T K</au><au>Day, D G</au><au>Stewart, J A</au><au>Jenkins, J N</au><au>Stewart, W C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>19</volume><issue>1</issue><spage>35</spage><epage>40</epage><pages>35-40</pages><issn>0950-222X</issn><eissn>1476-5454</eissn><coden>EYEEEC</coden><abstract>Purpose
To compare the efficacy and safety of brimonidine 0.2%
vs
unoprostone 0.15%, both added to timolol maleate 0.5% each given twice daily.
Methods
In this prospective, multi-centred, double-masked, crossover comparison, patients were randomized to one treatment group for a 6-week treatment period, and then crossed over to the opposite treatment. Measurements were performed at 0800, 1000, 1600, 1800, and 2000 h at baseline and at the end of each treatment period.
Results
In all, 33 patients entered this trial and 29 completed. The baseline trough intraocular pressure (IOP) was 23.3±2.4 and the diurnal curve IOP was 22.0±1.3 mmHg. For the brimonidine and timolol maleate treatment group, the trough IOP was 21.6±3.3 and the diurnal curve IOP was 19.8±2.1 mmHg, while the timolol and unoprostone treatment showed a trough IOP of 20.9±3.8 and a diurnal curve IOP of 19.3±2.4 mmHg. There was no significant difference between treatment groups at any time point for the diurnal curve, or in the reduction from baseline (
P
>0.05). Both treatments failed to statistically reduce the IOP from baseline at 1800 h. There was no difference between treatment groups regarding ocular and systemic unsolicited adverse events, but patients admitted to more dryness (
P
=0.02) and burning upon instillation (
P
<0.0001) with unoprostone by survey.
Conclusion
Brimonidine 0.2% or unoprostone 0.15% added to timolol maleate 0.5% provide similar efficacy and safety throughout the daytime diurnal curve.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>15094733</pmid><doi>10.1038/sj.eye.6701392</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-222X |
| ispartof | Eye (London), 2005-01, Vol.19 (1), p.35-40 |
| issn | 0950-222X 1476-5454 |
| language | eng |
| recordid | cdi_proquest_journals_218342977 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antihypertensive Agents - administration & dosage Antihypertensive Agents - adverse effects Biological and medical sciences Brimonidine Tartrate clinical-study Cross-Over Studies Dinoprost - administration & dosage Dinoprost - adverse effects Dinoprost - analogs & derivatives Double-Blind Method Drug Administration Schedule Drug Therapy, Combination Female Glaucoma Glaucoma and intraocular pressure Glaucoma, Open-Angle - drug therapy Glaucoma, Open-Angle - physiopathology Humans Intraocular Pressure - drug effects Laboratory Medicine Male Medical sciences Medicine Medicine & Public Health Middle Aged Ocular Hypertension - drug therapy Ophthalmology Pharmaceutical Sciences/Technology Prospective Studies Quinoxalines - administration & dosage Quinoxalines - adverse effects Surgery Surgical Oncology Timolol - administration & dosage Timolol - adverse effects Treatment Outcome |
| title | Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A39%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brimonidine%200.2%25%20vs%20unoprostone%200.15%25%20both%20added%20to%20timolol%20maleate%200.5%25%20given%20twice%20daily%20to%20patients%20with%20primary%20open-angle%20glaucoma%20or%20ocular%20hypertension&rft.jtitle=Eye%20(London)&rft.au=Sharpe,%20E%20D&rft.date=2005-01-01&rft.volume=19&rft.issue=1&rft.spage=35&rft.epage=40&rft.pages=35-40&rft.issn=0950-222X&rft.eissn=1476-5454&rft.coden=EYEEEC&rft_id=info:doi/10.1038/sj.eye.6701392&rft_dat=%3Cproquest_cross%3E971591031%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218342977&rft_id=info:pmid/15094733&rfr_iscdi=true |